Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more
Mega Lifesciences Public Company Limited (MEGA-R) - Net Assets
Latest net assets as of June 2025: ฿9.95 Billion THB
Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA-R) has net assets worth ฿9.95 Billion THB as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (฿14.31 Billion) and total liabilities (฿4.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ฿9.95 Billion |
| % of Total Assets | 69.49% |
| Annual Growth Rate | 19.15% |
| 5-Year Change | 41.52% |
| 10-Year Change | 127.86% |
| Growth Volatility | 31.58 |
Mega Lifesciences Public Company Limited - Net Assets Trend (2010–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mega Lifesciences Public Company Limited (2010–2024)
The table below shows the annual net assets of Mega Lifesciences Public Company Limited from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ฿9.88 Billion | +6.18% |
| 2023-12-31 | ฿9.30 Billion | +5.99% |
| 2022-12-31 | ฿8.78 Billion | +9.37% |
| 2021-12-31 | ฿8.03 Billion | +14.99% |
| 2020-12-31 | ฿6.98 Billion | +13.02% |
| 2019-12-31 | ฿6.18 Billion | +7.87% |
| 2018-12-31 | ฿5.72 Billion | +9.15% |
| 2017-12-31 | ฿5.24 Billion | +12.06% |
| 2016-12-31 | ฿4.68 Billion | +7.96% |
| 2015-12-31 | ฿4.33 Billion | +8.96% |
| 2014-12-31 | ฿3.98 Billion | +7.74% |
| 2013-12-31 | ฿3.69 Billion | +127.06% |
| 2012-12-31 | ฿1.63 Billion | +23.36% |
| 2011-12-31 | ฿1.32 Billion | +55.11% |
| 2010-12-31 | ฿849.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mega Lifesciences Public Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 774.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ฿7.76 Billion | 78.52% |
| Other Components | ฿2.12 Billion | 21.48% |
| Total Equity | ฿9.88 Billion | 100.00% |
Mega Lifesciences Public Company Limited Competitors by Market Cap
The table below lists competitors of Mega Lifesciences Public Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Philex Mining Corporation
PINK:PXMFF
|
$320.10 Million |
|
Beijing InterAct Technology Co Ltd
SHE:300419
|
$320.32 Million |
|
El Pollo Loco Holdings Inc
NASDAQ:LOCO
|
$320.34 Million |
|
Webjet Limited
PINK:WEBJF
|
$320.47 Million |
|
Jiangsu Jiangnan Water Co Ltd
SHG:601199
|
$319.96 Million |
|
Shanghai Fudan Forward S&T Co Ltd
SHG:600624
|
$319.93 Million |
|
Origin Enterprises plc
PINK:ORENF
|
$319.88 Million |
|
UCO Bank
NSE:UCOBANK
|
$319.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mega Lifesciences Public Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,302,162,000 to 9,876,759,000, a change of 574,597,000 (6.2%).
- Net income of 2,012,481,000 contributed positively to equity growth.
- Dividend payments of 1,394,568,000 reduced retained earnings.
- Other comprehensive income decreased equity by 88,210,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ฿2.01 Billion | +20.38% |
| Dividends Paid | ฿1.39 Billion | -14.12% |
| Other Comprehensive Income | ฿-88.21 Million | -0.89% |
| Other Changes | ฿44.89 Million | +0.45% |
| Total Change | ฿- | 6.18% |
Book Value vs Market Value Analysis
This analysis compares Mega Lifesciences Public Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.82x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.03x to 2.82x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | ฿1.77 | ฿32.00 | x |
| 2012-12-31 | ฿2.20 | ฿32.00 | x |
| 2013-12-31 | ฿4.94 | ฿32.00 | x |
| 2014-12-31 | ฿4.60 | ฿32.00 | x |
| 2015-12-31 | ฿5.01 | ฿32.00 | x |
| 2016-12-31 | ฿5.39 | ฿32.00 | x |
| 2017-12-31 | ฿6.04 | ฿32.00 | x |
| 2018-12-31 | ฿6.59 | ฿32.00 | x |
| 2019-12-31 | ฿7.09 | ฿32.00 | x |
| 2020-12-31 | ฿7.98 | ฿32.00 | x |
| 2021-12-31 | ฿9.18 | ฿32.00 | x |
| 2022-12-31 | ฿10.07 | ฿32.00 | x |
| 2023-12-31 | ฿10.67 | ฿32.00 | x |
| 2024-12-31 | ฿11.33 | ฿32.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mega Lifesciences Public Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 20.38%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.12%
- • Asset Turnover: 1.08x
- • Equity Multiplier: 1.44x
- Recent ROE (20.38%) is below the historical average (21.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 35.19% | 9.39% | 1.48x | 2.54x | ฿326.33 Million |
| 2012 | 34.66% | 9.31% | 1.44x | 2.58x | ฿395.32 Million |
| 2013 | 16.90% | 8.87% | 1.08x | 1.77x | ฿254.76 Million |
| 2014 | 13.77% | 7.09% | 1.15x | 1.69x | ฿150.05 Million |
| 2015 | 16.05% | 8.76% | 1.04x | 1.76x | ฿262.28 Million |
| 2016 | 16.99% | 9.02% | 1.11x | 1.70x | ฿326.93 Million |
| 2017 | 21.22% | 11.59% | 1.10x | 1.66x | ฿588.36 Million |
| 2018 | 21.07% | 11.66% | 1.07x | 1.68x | ฿633.58 Million |
| 2019 | 18.44% | 10.23% | 1.06x | 1.71x | ฿521.02 Million |
| 2020 | 20.02% | 11.06% | 1.09x | 1.67x | ฿696.89 Million |
| 2021 | 24.33% | 13.77% | 1.07x | 1.66x | ฿1.15 Billion |
| 2022 | 25.54% | 14.29% | 1.07x | 1.67x | ฿1.36 Billion |
| 2023 | 21.42% | 12.71% | 1.08x | 1.56x | ฿1.06 Billion |
| 2024 | 20.38% | 13.12% | 1.08x | 1.44x | ฿1.02 Billion |
Industry Comparison
This section compares Mega Lifesciences Public Company Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $200,940,802
- Average return on equity (ROE) among peers: -250.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mega Lifesciences Public Company Limited (MEGA-R) | ฿9.95 Billion | 35.19% | 0.44x | $320.06 Million |
| Eternal Energy Public Company Limited (EE) | $144.95 Million | 37.64% | 2.56x | $10.10 Million |
| Techlead NPN Public Company Limited (TL) | $256.93 Million | -538.97% | 0.06x | $19.34 Million |